Experienced in Autosomal Dominant Hyper IgE Syndrome

Dr. Lihua Budde

Hematology | Oncology
Elizabeth Lihua Budde, M.D., PH.D.
1500 Duarte Rd, 
Duarte, CA 
Clinical Trials:Currently Recruiting for 1 Trial
24 Years of Experience
Experienced in Autosomal Dominant Hyper IgE Syndrome
Elizabeth Lihua Budde, M.D., PH.D.
1500 Duarte Rd, 
Duarte, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Lihua Budde is a Hematologist and an Oncologist in Duarte, California. Dr. Budde has been practicing medicine for over 24 years and is rated as an Experienced provider by MediFind in the treatment of Autosomal Dominant Hyper IgE Syndrome. Her top areas of expertise are Non-Hodgkin Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma (MCL), Bone Marrow Aspiration, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 91 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in WA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Group
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Elizabeth Lihua Budde, M.D., PH.D.
1500 Duarte Rd, Duarte, CA 91010
Other Locations
City Of Hope Comprehensive Cancer Center-Duarte
1500 Duarte Rd, Duarte, CA 91010

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 2 Study to Evaluate CD19-Specific Chimeric Antigen Receptor (CAR)-T Cells Combined With Acalabrutinib for Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
A Phase 2 Study to Evaluate CD19-Specific Chimeric Antigen Receptor (CAR)-T Cells Combined With Acalabrutinib for Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Enrollment Status: Recruiting
Publish Date: November 26, 2025
Intervention Type: Drug, Biological
Study Drugs: Acalabrutinib, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
Study Phase: Phase 2
An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Drug
Study Drugs: Acalabrutinib, Rituximab, Lenalidomide
Study Phase: Phase 1/Phase 2
A Phase II Trial of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With or Without Brentuximab Vedotin Plus Nivolumab, Followed by Nivolumab Consolidation for Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin Lymphoma
A Phase II Trial of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With or Without Brentuximab Vedotin Plus Nivolumab, Followed by Nivolumab Consolidation for Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: October 03, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Nivolumab, Vinblastine
Study Phase: Phase 2
Phase I Study of Cellular Immunotherapy Using T Cells Lentivirally Transduced to Express a CD123-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR for Patients With CD123+ Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
Phase I Study of Cellular Immunotherapy Using T Cells Lentivirally Transduced to Express a CD123-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR for Patients With CD123+ Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Cyclophosphamide, Fludarabine, CD123CAR-CD28-CD3zeta-EGFRt-Expressing T Lymphocytes
Study Phase: Phase 1
A Phase 1/2 Trial of Pembrolizumab in Combination With Blinatumomab in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
A Phase 1/2 Trial of Pembrolizumab in Combination With Blinatumomab in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: May 30, 2025
Intervention Type: Biological, Other
Study Drugs: Blinatumomab, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase I Study of Intratumoral Injections of CpG-STAT3 siRNA (CAS3/SS3) in Combination With Local Radiation in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL)
A Phase I Study of Intratumoral Injections of CpG-STAT3 siRNA (CAS3/SS3) in Combination With Local Radiation in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Withdrawn
Publish Date: April 25, 2024
Intervention Type: Biological, Radiation
Study Drug: CpG-STAT3 siRNA CAS3/SS3
Study Phase: Phase 1
A Phase 1 / 2 Study to Evaluate the Safety and Tolerability of Adoptively Transferred Autologous T Cells in Patients With Relapsed Refractory Multiple Myeloma
A Phase 1 / 2 Study to Evaluate the Safety and Tolerability of Adoptively Transferred Autologous T Cells in Patients With Relapsed Refractory Multiple Myeloma
Enrollment Status: Suspended
Publish Date: January 16, 2024
Intervention Type: Biological
Study Drug: NEXI-002 T Cells
Study Phase: Phase 1/Phase 2
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Enrollment Status: Terminated
Publish Date: October 31, 2023
Intervention Type: Drug
Study Drugs: BL-8040 CD34-Positive Hematopoietic Cells, Nelarabine
Study Phase: Phase 2
A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: August 13, 2018
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Terminated
Publish Date: June 21, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

89 Total Publications

Copanlisib in combination with venetoclax in patients with relapsed/refractory mantle cell lymphoma.
Copanlisib in combination with venetoclax in patients with relapsed/refractory mantle cell lymphoma.
Journal: Leukemia & lymphoma
Published: October 31, 2025
Similar Doctors
Advanced in Autosomal Dominant Hyper IgE Syndrome
Dr. Khosrow Mahdavi
Oncology
Advanced in Autosomal Dominant Hyper IgE Syndrome
Dr. Khosrow Mahdavi
Oncology

UCI Health-Costa Mesa Home Infusion Pharmacy

1640 Newport Blvd Ste 400, 
Costa Mesa, CA 
 (35.4 miles away)
949-999-2400
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Khosrow Mahdavi is an Oncologist in Costa Mesa, California. Dr. Mahdavi is rated as a Distinguished provider by MediFind in the treatment of Autosomal Dominant Hyper IgE Syndrome. His top areas of expertise are Myelodysplastic Syndrome (MDS), Inflammatory Breast Cancer, Hemochromatosis, Paget Disease of the Breast, and Bone Marrow Aspiration.

Experienced in Autosomal Dominant Hyper IgE Syndrome
Dr. Mohamad Barakat
Hematology | Oncology
Experienced in Autosomal Dominant Hyper IgE Syndrome
Dr. Mohamad Barakat
Hematology | Oncology

Accetta Institute Of Womens Health Inc.

19671 Beach Blvd Ste 315, 
Huntington Beach, CA 
 (31.7 miles away)
714-252-9415
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mohamad Barakat is a Hematologist and an Oncologist in Huntington Beach, California. Dr. Barakat is rated as an Experienced provider by MediFind in the treatment of Autosomal Dominant Hyper IgE Syndrome. His top areas of expertise are Shwartzman Phenomenon, Iron Deficiency Anemia, Childhood Iron Deficiency Anemia, and Smoldering Multiple Myeloma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Budde's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 34 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile